Risk of Coronavirus Disease 2019 Messenger RNA Vaccination-Associated Myocarditis and Pericarditis – A Systematic Review of Population-Based Data

References

• Bozkurt B, Kamat I, Hotez PJ. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144(6):471–484. doi:10.1161/CIRCULATIONAHA.121.056135.
   PubMed Web of Science ®Google Scholar
• Kim HW, Jenista ER, Wendell DC, et al. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol. 2021;6(10):1196–1201. doi:10.1001/jamacardio.2021.2828
   PubMed Web of Science ®Google Scholar
• Dionne A, Sperotto F, Chamberlain S, et al. Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children. JAMA Cardiol. 2021;6(12):1446–1450. doi:10.1001/jamacardio.2021.3471
   PubMed Web of Science ®Google Scholar
• Truong DT, Dionne A, Muniz JC, et al. Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: suspected Myocarditis After COVID-19 Vaccination. Circulation. 2022;145(5):345–356. doi:10.1161/CIRCULATIONAHA.121.056583
   PubMed Web of Science ®Google Scholar
• Woo W, Kim AY, Yon DK, et al. Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine. J Med Virol. 2022;94(4):1566–1580. doi:10.1002/jmv.27501
   PubMed Web of Science ®Google Scholar
• Krug A, Stevenson J, Hoeg TB. BNT162b2 Vaccine-Associated Myo/Pericarditis in Adolescents: a Stratified Risk-Benefit Analysis. Eur J Clin Invest. 2022;52(5):e13759. doi:10.1111/eci.13759.
   PubMed Web of Science ®Google Scholar
• Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med. 2021;385(23):2140–2149. doi:10.1056/NEJMoa2109730
   PubMed Web of Science ®Google Scholar
• Oster ME, Shay DK, Su JR, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA. 2022;327(4):331–340. doi:10.1001/jama.2021.24110
   PubMed Web of Science ®Google Scholar
• Buchan SA, Chi Yon Seo CY, Johnson C, et al. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada. JAMA Netw Open. 2022;5(6):e2218505. doi:10.1001/jamanetworkopen.2022.18505
   PubMed Web of Science ®Google Scholar
• Yap J, Tham MY, Poh J, et al. Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting. Ann Acad Med Singap. 2022;51(2):96–100. doi:10.47102/annals-acadmedsg.2021425
   PubMed Web of Science ®Google Scholar
• Chua GT, Kwan MYW, Chui CSL, et al. Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. 2022;75(4):673–681. doi:10.1093/cid/ciab989
   PubMed Web of Science ®Google Scholar
• Husby A, Hansen JV, Fosbol E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ. 2021;375:e068665. doi:10.1136/bmj-2021-068665
   PubMedGoogle Scholar
• Lane S, Yeomans A, Shakir S. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature. BMJ Open. 2022;12(5):e059223. doi:10.1136/bmjopen-2021-059223.
   PubMed Web of Science ®Google Scholar
• Pillay J, Gaudet L, Wingert A, et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. BMJ. 2022;378:e069445. doi:10.1136/bmj-2021-069445
   PubMedGoogle Scholar
• Ling RR, Ramanathan K, Tan FL, et al. Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis. Lancet Respir Med. 2022;10(7):679–688. doi:10.1016/S2213-2600(22)00059-5
   PubMed Web of Science ®Google Scholar
• Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10(1):132. doi:10.1186/s40249-021-00915-3.
   PubMed Web of Science ®Google Scholar
• COVID-19 vaccine weekly safety report - 17-11-2022. Available from: https://www.tga.gov.au/news/covid-19-vaccine-safety-reports/covid-19-vaccine-safety-report-17-11-2022. Accessed December 5, 2022.
   Google Scholar
• Abraham N, Spruin S, Rossi T, et al. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: a Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines. Vaccine. 2022;40(32):4663–4671. doi:10.1016/j.vaccine.2022.05.048
   PubMed Web of Science ®Google Scholar
• Zaeema N, Julia L, Michelle S, et al. Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study. CMAJ. 2022;194(45):E1529–E1536. doi:10.1503/cmaj.220676
   PubMed Web of Science ®Google Scholar
• Nygaard U, Holm M, Bohnstedt C, et al. Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents. Pediatr Infect Dis J. 2022;41(1):e25–e28. doi:10.1097/INF.0000000000003389
   PubMed Web of Science ®Google Scholar
• Karlstad O, Hovi P, Husby A, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. JAMA Cardiol. 2022;7(6):600–612. doi:10.1001/jamacardio.2022.0583
   PubMed Web of Science ®Google Scholar
• Pfizer Vaccine Pharmacovigilance Investigation - BioNTech Comirnaty: monthly Focus #1 specific situations until September 30, 2021. Available from: https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-01-10-2021-au-14-10-2021. Accessed December 5, 2022.
   Google Scholar
• Li X, Lai FTT, Chua GT, et al. Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong. JAMA Pediatr. 2022;176(6):612–614. doi:10.1001/jamapediatrics.2022.0101
   PubMed Web of Science ®Google Scholar
• Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 Vaccination in Israeli Adolescents. N Engl J Med. 2022;386(10):998–999. doi:10.1056/NEJMc2116999
   PubMed Web of Science ®Google Scholar
• The 82nd Adverse Reaction Study Council of the Subcommittee on Immunization and Vaccine of the Ministry of Health and Welfare of Japan, the 8th Safety Measures Study Committee of the Subcommittee on Pharmaceutical Safety Measures of the Pharmaceutical Affairs and Food Sanitation Council in 2022. Available from: https://www.mhlw.go.jp/stf/shingi2/0000208910_00046.html. Accessed December 5, 2022.
   Google Scholar
• Yamaguchi T, Iwagami M, Ishiguro C, et al. Updated report of COVID-19 vaccine safety monitoring in Japan: booster shots and paediatric vaccinations. Lancet Reg Health West Pac. 2022;27:100600. doi:10.1016/j.lanwpc.2022.100600
   PubMedGoogle Scholar
• Su WJ, Liu YL, Chang CH, et al. Risk of myocarditis and pericarditis following Coronavirus Disease 2019 messenger RNA vaccination - A nationwide study. medRxiv. 2022. doi:10.1016/j.jmii.2023.01.016
   Google Scholar
• Wong HL, Hu M, Zhou CK, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Lancet. 2022;399(10342):2191–2199. doi:10.1016/S0140-6736(22)00791-7
   PubMed Web of Science ®Google Scholar
• Goddard K, Lewis N, Fireman B, et al. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Vaccine. 2022;40(35):5153–5159. doi:10.1016/j.vaccine.2022.07.007
   PubMed Web of Science ®Google Scholar
• Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022;28(2):410–422. doi:10.1038/s41591-021-01630-0
   PubMed Web of Science ®Google Scholar
• Patone M, Mei XW, Handunnetthi L, et al. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. Circulation. 2022;146(10):743–754. doi:10.1161/CIRCULATIONAHA.122.059970
   PubMed Web of Science ®Google Scholar
• Coronavirus vaccine – summary of Yellow Card reporting. Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting. Accessed December 5, 2022.
   Google Scholar
• The Paul Ehrlich Institute, the Germany Federal Ministry of Health. Safety Report: suspected cases of adverse events and vaccine-related complications following vaccination against COVID-19 from 27 December 2020 (start of vaccination campaign) to 31 December 2021. Available from: https://www.pei.de/EN/newsroom/dossier/coronavirus/medicine-safety.html. Accessed December 5, 2022.
   Google Scholar
• Massari M, Alegiani SS, Morciano C, et al. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: a multi-database, self-controlled case series study. PLoS Med. 2022;19(7):e1004056. doi:10.1371/journal.pmed.1004056
   PubMed Web of Science ®Google Scholar
• Lee DS, Kim JW, Lee KL, et al. Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: a nationwide observational study. Int J Infect Dis. 2022;118:173–182. doi:10.1016/j.ijid.2022.03.007
   PubMed Web of Science ®Google Scholar
• Kim S, Hwang I, Ko M, Kwon Y, Lee YK. Safety monitoring of COVID-19 vaccination among adolescents aged 12 to 17 years old in the Republic of Korea. Osong Public Health Res Perspect. 2022;13(3):230–237. doi:10.24171/j.phrp.2022.0122.
   PubMedGoogle Scholar
• Korea Disease Control and Prevention Agency, the South Korean Ministry of Welfare and Health. Weekly analysis of adverse reactions after COVID-19 vaccination (week 90); 2022. Available from: https://ncv.kdca.go.kr/board.es?mid=a12609010000&bid=0032#content. Accessed December 5, 2022.
   Google Scholar
• Centers for Disease Prevention and Control. Update on myocarditis following mRNA COVID-19 vaccination. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-06-22-23/03-covid-shimabukuro-508.pdf. Accessed December 5, 2022.
   Google Scholar
• Le Vu S, Bertrand M, Jabagi MJ, et al. Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines. Nat Commun. 2022;13(1):3633. doi:10.1038/s41467-022-31401-5
   PubMed Web of Science ®Google Scholar
• Dickerman BA, Madenci AL, Gerlovin H, et al. Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans. JAMA Intern Med. 2022;182(7):739–746. doi:10.1001/jamainternmed.2022.2109
   PubMed Web of Science ®Google Scholar